Medicine and Dentistry
Adenoma
15%
Adoptive Immunotherapy
13%
Adverse Event
10%
Arm
11%
Atezolizumab
20%
Autoimmune Pancreatitis
14%
Bevacizumab
26%
Bile Duct
8%
Biliary Tract Drainage
22%
Biological Marker
10%
Cancer
24%
Cholangiocarcinoma
14%
Choledochoduodenostomy
13%
Cholestasis
8%
Chronic Kidney Disease
11%
Chronic Pancreatitis
18%
Clinical Study
7%
Clinical Trial
8%
Cohort Analysis
8%
Colonoscopy
8%
Colorectal Cancer
15%
Colorectal Tumor
8%
Combination Therapy
7%
Computer Assisted Tomography
12%
Confocal Laser Scanning Microscopy
14%
CpG Island
10%
Crohn's Disease
16%
Diagnosis
24%
Diagnostic Accuracy
7%
Differential Diagnosis
16%
Disease
16%
Duodenum
7%
Echography
29%
Endoscopic Submucosal Dissection
20%
Endoscopic Ultrasound
69%
Endoscopic Ultrasound Guided Fine Needle Biopsy
26%
Endoscopy
43%
Eradication Therapy
11%
Fine-Needle Aspiration
25%
First-Line Chemotherapy
9%
Fluorouracil
9%
Gastrointestinal Stromal Tumor
35%
Hazard Ratio
9%
Helicobacter Infection
13%
Helicobacter Pylori
44%
Hepatocellular Carcinoma
35%
Image Enhanced Endoscopy
8%
Immunoglobulin G4
13%
Inflammatory Disorder
7%
Intraductal Papillary Mucinous Tumor
13%
Killer Cell
13%
Liver Function
8%
Lymph Node Metastasis
9%
Lymphadenopathy
7%
Lymphatic Follicle
13%
Lymphocyte
9%
Macrogol
13%
Magnifying Endoscopy
10%
Malignant Neoplasm
36%
Median Survival Time
8%
Meta-Analysis
10%
Meta-Regression
7%
Methylation
13%
microRNA
13%
Morphology
10%
Mucosa
10%
Multivariate Analysis
13%
Narrow Band Imaging
42%
Neoplasm
65%
Observational Study
13%
Obstructive Jaundice
7%
Odds Ratio
8%
Oncology
7%
Overall Survival
19%
Pancreas Adenocarcinoma
27%
Pancreas Cancer
57%
Pancreas Disease
16%
Pancreas Tumor
21%
Pancreatic Duct
8%
Pancreatitis
9%
Polyp
9%
Promoter Region
8%
Pylorus
27%
Ras Signaling
16%
Stenosis
15%
Steroid Therapy
7%
Steroid Treatment
8%
Stomach Cancer
52%
Stomach Mucosa
14%
Stomach Ulcer
7%
Surgery
8%
Transcatheter Arterial Chemoembolization
8%
Tyrosine-Kinase Inhibitor
7%
Ulcer
14%
Ulcerative Colitis
16%
Upper Digestive Tract
13%
Venous Ulcer
7%
Vermiform Appendix
8%
White Light Endoscopy
14%
Zoledronic Acid
13%
Pharmacology, Toxicology and Pharmaceutical Science
Adenoma
12%
Adjuvant
6%
Adverse Event
32%
Alpha Fetoprotein
12%
Antacid Agent
6%
Anticoagulation Therapy
6%
Atezolizumab
46%
Atrophic Gastritis
13%
Bevacizumab
60%
Biological Marker
11%
Bleeding
7%
Cabozantinib
6%
Capecitabine
21%
Cetuximab
6%
Chemotherapy
64%
Chronic Hepatitis B
6%
Cisplatin
19%
Clinical Trial
24%
Colon Polyposis
6%
Colorectal Adenoma
8%
Colorectal Cancer
17%
Colorectal Tumor
13%
Combination Therapy
15%
Comorbidity
6%
Crohn's Disease
7%
Diabetes Mellitus
6%
Disease
24%
Diseases
7%
Docetaxel
8%
Duodenum Ulcer
13%
End Stage Liver Disease
7%
Ethanol
6%
Fluoropyrimidine
13%
Fluorouracil
9%
Folinic Acid
6%
Gamma Urogastrone
8%
Gastrointestinal Hemorrhage
6%
Gastrointestinal Stromal Tumor
20%
Heat Shock Protein 70
6%
Helicobacter Infection
14%
Helicobacter Pylori
24%
Hepatitis B Virus
6%
Hypovitaminosis D
6%
Imatinib
20%
Immunoglobulin G4
6%
Immunotherapy
20%
Intestine Metaplasia
6%
Intestine Tumor
6%
Irinotecan
16%
Jejunum Ulcer
6%
Lenvatinib
12%
Liver Cell Carcinoma
72%
Liver Disease
6%
Liver Metastasis
6%
Malignant Neoplasm
24%
Metaplasia
12%
Metastatic Colorectal Cancer
16%
microRNA
13%
microRNA 124
6%
microRNA 31
7%
Monotherapy
7%
Motesanib
6%
Neoplasm
28%
Neuroendocrine Tumor
6%
Neutropenia
11%
Nilotinib
6%
Observational Study
13%
Omeprazole
6%
Oncolytic Herpes Virus
6%
Overall Survival
35%
Oxaliplatin
9%
Paclitaxel
14%
Pancreas Adenocarcinoma
10%
Pancreas Cancer
35%
Pancreas Islet Cell Tumor
13%
Placebo
13%
Precancer
13%
Prevalence
6%
Progression Free Survival
27%
Ramucirumab
13%
Regorafenib
6%
Remission
6%
Sclerosing Cholangitis
6%
Second-Line Chemotherapy
6%
Small Interfering RNA
6%
Solid Malignant Neoplasm
6%
Sorafenib
9%
Stomach Cancer
100%
Stomach Ulcer
8%
Sunitinib
26%
Taxane
8%
Trastuzumab
7%
Tremelimumab
6%
Tumor Necrosis Factor
6%
UFT
6%
Ulcer
11%
Vascular Disease
6%
Vasculotropin
6%
Xenobiotic Agent
6%
Zoledronic Acid
13%
Keyphrases
Abdominal Lymphadenopathy
6%
Abdominal Ultrasonography
8%
Advanced Gastric Cancer
20%
Advanced Hepatocellular Carcinoma
27%
Adverse Events
10%
Anti-oncomir
6%
Atezolizumab Plus Bevacizumab
33%
Biliary Tract Carcinoma
8%
Cancer Risk
10%
Cape
6%
CapeOX
6%
Chemotherapy
16%
Clinical Impact
6%
Clinical Outcomes
13%
Clinical Practice
7%
Combination Therapy
13%
Common Genetic Variants
13%
Complete Response
7%
Confocal Laser Endomicroscopy
6%
Diagnostic Biomarker
6%
Differential Diagnosis
7%
Distal Colon
6%
Docetaxel
10%
Endoscopic Features
6%
Endoscopic Pancreatic Stent
6%
Endoscopic Staging
6%
Endoscopic Ultrasonography
7%
Endoscopic Ultrasound
6%
Endoscopic Ultrasound-guided
8%
Endoscopic Ultrasound-guided Biliary Drainage (EUS-BD)
13%
Endoscopic Ultrasound-guided Choledochoduodenostomy
13%
Epigenome Evolution
6%
Esophageal Web
6%
EUS-guided Choledochoduodenostomy
6%
Feasibility Trial
6%
Food Taste
6%
Gastric Cancer
21%
Gastric Cancer Patients
11%
Gastrointestinal Stromal Tumor
13%
Gastrointestinal Submucosal Tumor
6%
Gene Aberrations
6%
Gene Polymorphism
7%
Helicobacter Pylori Eradication
6%
Hepatocellular Carcinoma
7%
IGF2 DMR
6%
IgG4-positive
7%
IgG4-related Sclerosing Cholangitis
13%
IL-1 Polymorphism
6%
Imatinib Failure
6%
Individual Response
6%
Interleukin-17 (IL-17)
6%
International Association
6%
Iron Therapy
6%
Lenvatinib
12%
Leukocyte DNA
6%
Liver Function
8%
Lymph Node Metastasis
7%
Magnifying Endoscopy with Narrow-band Imaging
6%
Metastatic Pancreatic Cancer
6%
MIF Gene
6%
MiR-146a rs2910164
10%
Motesanib
6%
Nationwide Survey
6%
New FP
6%
Odds Ratio
7%
Overall Survival
7%
Palliative Biliary Drainage
6%
Pancreatic Cancer
7%
Pancreatic Neuroendocrine Tumors (pNETs)
13%
Pancreatology
6%
Performance Status 2
6%
Periampullary Cancer
10%
Peutz-Jeghers Polyp
6%
Plummer-Vinson Syndrome
6%
Pre-microRNA
20%
Preoperative Diagnosis
6%
Prior Exposure
6%
Protease-activated Receptor 2 (PAR2)
6%
R0 Resection
6%
Ramucirumab
6%
Randomized Prospective Trial
6%
REG4
13%
Response to Food
6%
Rs11614913
10%
Rs3746444
13%
Second-look Endoscopy
6%
Single nucleotide Polymorphism
6%
Solid Pseudopapillary Tumor
6%
Steroid Treatment
14%
STI571
6%
Stomach Cancer
6%
Submucosal Hematoma
6%
Survey in Japan
6%
TNF Polymorphism
6%
Transabdominal
6%
Tremelimumab
6%
Tumor
8%
Two-step Method
6%
Ulcerative Colitis
13%
Ulcerative Colitis-associated Neoplasia
6%